oesophag
treat
empir
fluconazol
oesophagoscopi
perform
symptom
fail
settl
initi
categori
ib
recommend
specif
treatment
oesophag
case
fail
settl
empir
therapi
direct
caus
identifi
biopsi
cultur
antimicrobi
sensit
test
categori
iii
recommend
oesophag
suspect
patient
experi
pain
swallow
without
symptom
reflux
dysphagia
common
caus
organ
candida
spp
persist
recurr
oesophag
candidiasi
decreas
haart
era
often
indic
fail
poor
hiv
viral
control
treatment
prophylaxi
fluconazol
altern
agent
subject
recent
cochran
review
review
show
fluconazol
superior
nystatin
term
clinic
cure
clotrimazol
term
mycolog
cure
also
show
itraconazol
similar
fluconazol
efficaci
fluconazol
use
pregnanc
major
hivrel
infecti
caus
oesophag
includ
herp
simplex
cytomegaloviru
infect
caus
ulcer
may
coexist
candidiasi
especi
count
cellsml
idiopath
ulcer
also
common
caus
oesophag
symptom
includ
pillassoci
ulcer
associ
number
medic
commonli
mid
oesophagu
doxycyclin
relat
antimicrobi
nonsteroid
antiinflammatori
drug
potassium
supplement
iron
tablet
commonest
caus
like
encount
hivseroposit
patient
randomis
trial
demonstr
initi
empir
therapi
candidiasi
reason
initi
approach
uncompl
oesophag
oesophagoscopi
perform
symptom
fail
resolv
empir
trial
azol
adequ
appropri
specimen
must
taken
enabl
histolog
virolog
diagnos
togeth
cultur
antifung
suscept
test
identif
azoleresist
candida
strain
azolesensit
strain
treat
fluconazol
mg
po
day
categori
ib
recommend
prefer
azol
due
experi
superior
bioavail
comparison
itraconazol
altern
includ
caspofungin
mg
load
dose
mg
day
iv
liposom
amphotericin
b
mg
kg
day
iv
use
durat
fluconazol
sideeffect
profil
caspofungin
efficaci
clinic
trial
make
prefer
agent
azol
therapi
use
categori
iii
recommend
case
primari
secondari
prophylaxi
oropharyng
oesophag
candidiasi
larg
abandon
due
rapid
emerg
resist
one
random
clinic
trial
suggest
individu
frequent
symptomat
relaps
continu
fluconazol
treatment
mg
per
day
effect
intermitt
treatment
prevent
relaps
reduc
colon
studi
intermitt
treatment
group
requir
median
four
treatment
cours
per
year
high
incid
azol
resist
compar
group
continu
treatment
intermitt
self
treatment
fluconazol
may
appropri
individu
persist
low
cell
count
less
frequent
relaps
like
appropri
strategi
individu
histori
relaps
oropharyng
candidiasi
haart
era
secondari
prophylaxi
reserv
select
case
categori
iv
recommend
cmv
oesophag
treat
ganciclovir
mgkg
bd
iv
week
symptomssign
resolv
categori
iii
recommend
valganciclovir
may
substitut
iv
ganciclovir
mg
bd
oral
durat
symptom
sever
enough
interfer
oral
absorpt
basi
studi
show
efficaci
cmv
diseas
transplant
patient
pauciti
data
hivrel
cmv
diseas
gastrointestin
tract
categori
iv
recommend
secondari
cmv
prophylaxi
oesophag
diseas
routin
indic
unless
concomit
ophthalmolog
diseas
herp
simplex
oesophag
treat
aciclovir
mgkg
tid
iv
follow
mg
five
time
day
oral
total
day
categori
iii
recommend
oral
valaciclovir
g
bd
oral
see
herp
virus
discuss
prophylaxi
hsv
foscarnet
mgkg
bd
iv
use
case
ganciclovirresist
cmv
mgkg
bd
tid
aciclovirresist
hsv
present
infecti
oesophag
earli
initi
haart
consid
categori
iv
recommend
elsewher
guidelin
earli
initi
haart
favour
basi
improv
surviv
without
aid
progress
death
seen
haart
initi
within
first
two
week
treatment
opportunist
infect
recommend
extrapol
seri
case
relat
oesophag
opportunist
infect
also
support
evid
function
immunolog
benefit
antiretrovir
organ
candida
spp
diarrhoea
common
problem
peopl
hiv
resourcepoor
resourcerich
set
regardless
antiretrovir
exposur
prehaart
era
hivseroposit
individu
experienc
diarrhoea
among
european
patient
count
cellsml
would
expect
develop
diarrhoea
within
year
within
year
resourcepoor
area
incid
sever
continu
higher
earli
clinic
observ
confirm
diarrhoeal
ill
link
reduc
qualiti
life
poorer
surviv
diarrhoea
may
present
symptom
lymphoma
kaposi
sarcoma
may
affect
take
antiretrovir
therapi
art
induc
medic
may
result
incomplet
defin
direct
effect
hiv
gut
mucosa
term
hivassoci
enteropathi
list
caus
diarrhoea
hivseroposit
individu
see
tabl
everi
effort
made
confirm
specif
diagnosi
patient
signific
immunosuppress
categori
iv
recommend
variou
algorithm
propos
investig
andor
empir
manag
chronic
hivrel
diarrhoea
three
loos
stool
day
western
tropic
set
parasit
caus
like
prolong
diarrhoea
consider
weight
loss
count
cellsml
may
coexist
cmv
mycobacteri
infect
acut
diarrhoea
due
bacteria
virus
background
epidemiolog
acut
diarrhoea
common
peopl
live
hiv
especi
older
lower
cell
count
evid
confirm
increas
carriag
pathogen
mani
caus
viral
bacteri
pathogen
spars
risk
factor
socioeconom
circumst
travel
sexual
behaviour
control
studi
hivrel
diarrhoea
includ
investig
virus
cytomegaloviru
cmv
anecdot
evid
increas
sever
frequenc
virus
associ
gastroenter
hiv
includ
norovirus
rotaviru
report
implic
coronaviru
may
coexist
bacteri
pathogen
acut
diarrhoea
adenoviru
may
coexist
cmv
patient
chronic
diarrhoea
herp
simplex
infect
caus
relaps
sever
proctocol
treat
aciclovir
mg
five
time
daili
po
valaciclovir
g
bd
po
day
sever
infect
may
necessit
aciclovir
iv
mgkg
tid
initi
part
therapi
prophylaxi
consid
recurr
diseas
see
herp
simplex
viru
hsv
infect
cmv
coliti
present
acut
diarrhoea
specif
address
later
major
opportunist
infect
gastrointestin
tract
sexual
transmit
agent
neisseria
gonorrhoea
chlamydia
trachomati
includ
lymphogranuloma
venereum
consid
suscept
individu
invas
nontyphoid
salmonellosi
nt
recogn
earli
hiv
epidem
strongli
associ
immunosuppress
western
tropic
set
associ
hiv
typhoid
paratyphoid
patient
hiv
nt
infect
present
febril
ill
sepsi
syndrom
diarrhoea
may
absent
less
promin
featur
hiv
neg
individu
bacteri
pathogen
includ
clostridium
difficil
campylobact
spp
shigella
spp
c
difficil
common
caus
diarrhoea
us
cohort
studi
describ
british
resourcepoor
set
implic
case
acut
diarrhoea
studi
span
preand
posthaart
era
common
aidsdefin
ill
like
reflect
greater
exposur
risk
factor
hospit
broadspectrum
antimicrobi
use
treatment
toxoplasmosi
specif
use
acidlow
therapi
attent
modifi
risk
factor
like
essenti
control
infect
hivseroposit
individu
clinic
spectrum
caus
acut
diarrhoea
rang
asymptomat
infect
sever
dehydr
death
viral
gastroenter
typic
present
short
prodrom
mild
fever
vomit
follow
day
nonbloodi
wateri
diarrhoea
viral
gastroenter
usual
selflimit
bacteria
caus
gastroenter
may
caus
bloodi
diarrhoea
abdomin
pain
bacteraemia
common
still
unusu
hivrel
campylobact
shigella
infect
present
symptom
clostridium
difficil
infect
similar
hivseroneg
individu
case
seri
show
c
difficil
infect
sever
hivseroposit
individu
though
case
report
complic
toxic
megacolon
leukaemoid
reaction
exist
popul
stool
blood
cultur
includ
routin
diagnost
workup
diarrhoea
hiv
categori
iv
recommend
uk
c
difficil
toxin
assess
andor
cultur
carri
hivseroposit
individu
present
acut
diarrhoea
categori
iv
recommend
bacteri
caus
suspect
histori
antimicrobi
therapi
may
indic
principl
therapi
hivseroneg
individu
acut
bacteri
diarrhoea
individu
preserv
count
cellsml
usual
requir
treatment
categori
iv
recommend
gener
individu
present
acut
bacteri
diarrhoea
count
cellsml
therapi
indic
categori
iv
recommend
indic
choic
guid
vitro
sensit
pattern
antimicrobi
suscept
test
request
routin
whilst
major
isol
sensit
ciprofloxacin
mg
bd
po
day
increas
report
resist
campylobact
spp
salmonella
spp
addit
relationship
fluoroquinolon
c
difficil
infect
mrsa
colon
result
less
empir
use
agent
treatment
therefor
reserv
confirm
case
guid
sensit
test
except
case
patient
present
sign
sepsi
sever
symptom
benefit
empir
treatment
may
outweigh
potenti
risk
categori
iv
recommend
c
difficil
infect
first
step
stop
aetiolog
antibiot
respons
specif
therapi
metronidazol
mg
tid
po
day
vancomycin
mg
po
qid
day
similar
hivseroposit
hivseroneg
individu
complic
appear
less
common
hiv
first
episod
c
difficil
infect
treat
metronidazol
consider
vancomycin
fulmin
diseas
relaps
diseas
nonrespons
infect
categori
iv
recommend
follow
recommend
treatment
hivseroneg
popul
outlin
depart
health
guidelin
therapi
indic
c
difficil
infect
regardless
cell
count
acut
bacteri
diarrhoea
hivseroposit
individu
count
cellsml
usual
requir
treatment
treat
count
cellsml
categori
iv
recommend
acut
bacteri
diarrhoea
treat
per
suscept
test
local
guidanc
categori
iv
recommend
c
difficil
infect
treat
metronidazol
mg
tid
po
day
vancomycin
reserv
sever
relaps
metronidazol
nonrespons
infect
categori
iv
recommend
trimethoprimsulphamethoxazol
tmpsmx
cotrimoxazol
reduc
incid
infecti
diarrhoea
prehaart
era
retrospect
studi
suggest
introduct
antiretrovir
therapi
includ
zidovudin
monotherapi
effect
target
antimicrobi
prophylaxi
prevent
recurr
nontyphoid
salmonella
durat
antimicrobi
prophylaxi
agent
fluoroquinolon
need
exceed
day
patient
establish
haart
incid
bacteri
diarrhoea
declin
steadili
introduct
haart
therefor
haart
mainstay
prevent
bacteri
diarrhoea
categori
iii
recommend
prehaart
era
retin
common
present
cmv
follow
gastrointestin
diseas
see
tabl
list
potenti
clinic
manifest
cmv
gi
tract
data
incid
cmv
obtain
popul
retin
major
affect
individu
count
cellsml
episod
occur
count
cellsml
sinc
advent
haart
cmv
infect
may
occasion
occur
part
immun
reconstitut
syndrom
overal
incid
cmv
individu
live
hiv
dramat
reduc
cmv
may
affect
section
gut
indic
tabl
endoscopi
may
reveal
classic
cmv
ulcer
gut
mucosa
biopsi
histopatholog
review
may
identifi
characterist
intranuclear
intracytoplasm
owl
eye
inclus
absenc
ulcer
make
diagnosi
cmv
coliti
unlik
cultur
cmv
biopsi
materi
suffici
diagnosi
gut
infect
immunosuppress
individu
may
shed
viru
without
intestin
diseas
first
line
treatment
cmv
coliti
intraven
ganciclovir
mgkg
twice
daili
day
categori
ib
recommend
immedi
optim
haart
consid
categori
iv
recommend
cmv
coliti
tradit
treat
ganciclovir
mgkg
bd
iv
day
caution
use
initi
treatment
oral
medic
valganciclovir
theoret
concern
decreas
absorpt
hiv
nonhivrel
case
cmv
coliti
success
treat
intraven
foscarnet
mgkg
twice
daili
day
use
altern
therapeut
drug
monitor
may
requir
ensur
adequ
haart
absorpt
categori
iv
recommend
chronic
mainten
therapi
routin
recommend
gastrointestin
diseas
unless
patient
relaps
induct
therapi
ceas
individu
cmv
involv
gastrointestin
tract
prompt
ophthalmolog
evalu
exclud
concomit
cmv
retin
present
treatment
secondari
prophylaxi
initi
recommend
see
section
cmv
retin
continu
use
effect
haart
requir
prevent
relaps
cryptosporidium
protozoan
parasit
common
pathogen
hivantibodyposit
individu
chronic
diarrhoea
prehaart
era
greatest
risk
infect
individu
count
cellsml
predominantli
infect
small
bowel
mucosa
immunocompromis
patient
larg
bowel
extraintestin
site
may
involv
common
speci
infect
human
uk
c
homini
zoonot
speci
c
parvum
c
meleagridi
area
low
rate
environment
contamin
haart
wide
avail
cryptosporidiosi
incid
per
personyear
among
hivseroposit
individu
ingest
cryptosporidium
oocyst
lead
transmiss
parasit
faec
infect
anim
includ
human
contamin
water
suppli
viabl
oocyst
highli
resist
chlorin
transmiss
may
also
occur
sex
particularli
via
faecalor
rout
cryptosporidiosi
consid
individu
acut
subacut
histori
profus
nonbloodi
wateri
diarrhoea
immunocompet
individu
cryptosporidiosi
present
acut
selflimit
diarrhoeal
ill
may
accompani
nausea
abdomin
cramp
lowgrad
pyrexia
last
day
hivseroposit
individu
count
cellsml
worsen
symptom
stool
volum
litr
per
day
describ
although
commonli
litr
per
day
pass
malabsorpt
may
present
epithelium
pancreat
duct
biliari
tract
infect
cholang
pancreat
may
occur
individu
prolong
infect
scleros
cholang
present
right
upper
quadrant
pain
vomit
rais
alkalin
phosphatas
level
ziehlneelsen
auramin
phenol
acidfast
trichrom
stain
differenti
oocyst
yeast
oocyst
may
detect
easili
direct
immunofluoresc
enzymelink
immunosorb
assay
similar
sensit
pcr
techniqu
individu
profus
diarrhoea
cryptosporidiosi
may
detect
singl
stool
sampl
multipl
sampl
may
requir
less
sever
infect
oocyst
excret
may
intermitt
small
bowel
rectal
histolog
may
use
although
latter
low
sensit
diagnosi
individu
abdomin
pain
endoscop
retrograd
cholangiopancreatographi
ercp
may
reveal
ampullari
stenosi
scleros
cholang
associ
thicken
gall
bladder
wall
specif
treatment
target
cryptosporidium
directli
earli
haart
imper
associ
complet
resolut
infect
follow
restor
immun
function
individu
profus
diarrhoea
therapeut
drug
monitor
may
requir
confirm
adequ
absorpt
antiretrovir
agent
paromomycin
activ
anim
model
although
recent
metaanalysi
shown
evid
clinic
effect
studi
combin
paromomycin
azithromycin
report
substanti
reduct
stool
frequenc
volum
togeth
diminish
oocyst
shed
paromomycin
given
oral
mg
four
time
daili
g
twice
daili
week
dose
azithryomycin
mg
daili
howev
small
number
studi
limit
experi
combin
preclud
choic
front
line
therapi
nitazoxanid
approv
use
immunocompet
individu
shown
superior
placebo
sever
immunocompromis
use
nitazoxanid
given
dose
mg
twice
daili
day
may
requir
week
trial
also
investig
larger
dose
g
bd
po
anticryptosporidi
agent
chosen
nitazoxanid
prefer
agent
efficaci
limit
immunocompromis
patient
support
therapi
iv
fluid
replacementantimotil
agent
essenti
firstlin
treatment
cryptosporidiosi
effect
antiretrovir
therapi
categori
recommend
iii
nitazoxanid
effect
adult
children
sever
immunosuppress
categori
iib
recommend
use
optim
haart
continu
prevent
relaps
prevent
standard
drink
water
chlorin
techniqu
suffici
erad
parasit
specif
filtrat
employ
absolut
filter
requir
bottl
water
necessarili
safer
option
boil
water
advoc
background
epidemiolog
microsporidiosi
due
oblig
intracellular
parasit
relat
fungi
occur
sever
immunocompromis
individu
commonli
count
cellsml
speci
caus
gastrointestin
disturb
diarrhoea
cholang
genera
associ
upper
respiratori
ophthalm
infect
microsporidia
commonli
link
gastrointestin
ill
enterocytozoon
bieneusi
encephalitozoon
formerli
septata
intestinali
gut
infect
acquir
swallow
cyst
usual
water
prehaart
studi
show
variabl
preval
microsporidiosi
immunosuppress
hiv
popul
diarrhoea
incid
decreas
introduct
haart
wateri
nonbloodi
diarrhoea
associ
malabsorpt
commonest
present
gastrointestin
infect
scleros
cholang
may
occur
enceph
sinus
myositi
renal
ocular
dissemin
infect
also
describ
diagnosi
examin
three
stool
chromotrop
chemofluoresc
stain
often
suffici
diagnosi
stool
sampl
consist
neg
small
bowel
biopsi
perform
stain
giemsa
acidfast
haematoxylin
eosin
use
visual
microsporidia
biopsi
specimen
dissemin
infect
due
encephalitozoon
spp
organ
may
also
found
deposit
spun
urin
sampl
electron
microscopi
remain
gold
standard
confirm
speciat
pcr
may
use
identifi
speci
level
specif
treatment
microsporidi
infect
earli
haart
imper
associ
complet
resolut
gastrointestin
symptom
follow
restor
immun
function
therapeut
drug
monitor
may
requir
confirm
adequ
absorpt
antiretrovir
agent
thalidomid
may
effect
symptom
control
individu
e
bieneusi
may
respond
oral
fumagillin
mg
three
time
daili
day
signific
haematolog
toxic
agent
current
wide
avail
nitazoxanid
albendazol
itraconazol
also
studi
agent
albendazol
mg
twice
daili
day
recommend
initi
therapi
particularli
e
intestinali
categori
iii
recommend
entamoeba
histolyticadispar
describ
homosexu
men
hiv
epidem
reflect
increas
risk
behaviour
see
tabl
giardiasi
giardiasi
usual
present
chronic
diarrhoea
constitut
symptom
gi
symptom
includ
nausea
bloat
crampi
abdomin
pain
indigest
belch
prolong
diarrhoea
may
result
malabsorpt
state
giardiasi
treat
metronidazol
mg
tid
po
day
g
daili
day
tinidazol
mg
bd
po
day
g
po
categori
iii
recommend
see
tabl
altern
includ
albendazol
paromomycin
nitazoxanid
amoebiasi
entamoeba
histolytica
protozoan
caus
intestin
infect
includ
coliti
extraintestin
invas
diseas
commonli
liver
abscess
entamoeba
infect
commonli
seen
men
sex
men
fever
abdomin
pain
either
wateri
bloodi
diarrhoea
frequent
symptom
amoeb
coliti
occur
rang
count
limit
individu
tcell
count
cellsml
hepat
abscess
commonest
extraintestin
manifest
diagnosi
involv
microscopi
least
three
stool
sampl
detect
trophozoit
cyst
antigen
detect
pcr
stool
may
also
perform
endoscopi
biopsi
aid
diagnosi
stool
analysi
fail
confirm
diagnosi
diagnost
uncertainti
remain
serolog
employ
remain
posit
year
exposur
therefor
direct
identif
entamoeba
desir
extraintestin
lesion
diagnos
appropri
clinic
set
imag
combin
serolog
treatment
often
metronidazol
mg
tid
po
day
although
tinidazol
g
day
po
three
day
may
use
altern
agent
follow
diloxanid
fuorat
mg
tid
po
cyclospora
cayetanensi
coccidian
parasit
small
bowel
widespread
throughout
tropic
caus
larg
outbreak
foodborn
ill
usa
import
food
caus
prolong
wateri
diarrhoea
may
last
month
patient
hiv
biliari
involv
also
report
diagnosi
involv
microscop
detect
oocyst
fluoresc
microscopi
realtim
pcr
may
use
avail
clinic
parasitolog
respons
standard
dose
tmpsmx
mg
twice
daili
rapid
day
usual
suffici
ciprofloxacin
mg
twice
daili
altern
respons
slower
incomplet
categori
iib
relaps
describ
hivseroposit
patient
secondari
prophylaxi
tmpsmx
mg
three
time
week
ciprofloxacin
mg
three
time
week
need
absenc
effect
art
isospora
belli
isospora
belli
known
anim
host
widespread
geograph
caus
selflimit
small
bowel
diarrhoea
hivseroneg
individu
implic
case
chronic
hivrel
diarrhoea
tropic
occasion
caus
biliari
diseas
treatment
tradit
tmpsmx
mg
qid
po
day
though
mg
bd
appear
also
effect
categori
iii
recommend
secondari
prophylaxi
antibiot
mg
three
time
week
essenti
relaps
common
indirect
direct
evid
efficaci
ciprofloxacin
less
effect
altern
treatment
prophylaxi
anecdot
report
suggest
possibl
role
pyrimethamin
mgday
treatment
mgday
secondari
prophylaxi
patient
allerg
sulphonamid
strongyloid
stercorali
strongyloid
stercorali
gut
nematod
caus
chronic
gastrointestin
skin
problem
due
autoinfect
lifecycl
dissemin
caus
lifethreaten
hyperinfect
syndrom
immunosuppress
despit
anecdot
report
conclus
evid
infect
hyperinfect
common
patient
hiv
although
may
implic
immun
reconstitut
syndrom
corticosteroid
use
remain
major
factor
case
report
hyperinfect
syndrom
hivseroposit
individu
eosinophilia
present
patient
uncompl
infect
treat
ivermectin
mgkg
day
po
day
effect
altern
treatment
albendazol
mg
bd
po
day
categori
iii
recommend
case
report
hivseroposit
individu
highlight
import
follow
stool
specimen
repeat
treatment
parasit
appar
physician
repeat
initi
day
ivermectin
treatment
week
hyperinfect
treat
day
therapi
longer
larva
clear
basi
recommend
howev
larg
studi
nonhivrel
case
although
case
report
treatment
hiv
exist
serolog
stool
examin
check
interv
first
year
treatment
autoinfect
migrat
larva
may
erad
initi
treatment
